Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a lysine analogue of MK 421 and a gold-standard, long-acting angiotensin converting enzyme (ACE) inhibitor with an IC50 of 4.7 nM, validated for use in cardiovascular and renal research (APExBIO | Tieku & Hooper 1992). It exhibits high selectivity for ACE and negligible activity against aminopeptidases N, A, or W under standard assay conditions. Lisinopril dihydrate is water-soluble at ≥2.46 mg/mL (with gentle warming and ultrasonic treatment), stable at room temperature when desiccated, and supplied at ≥98% purity. It enables reproducible modeling of the renin-angiotensin system in hypertension, heart failure, diabetic nephropathy, and acute myocardial infarction studies. Stringent quality control by APExBIO ensures mass spectrometry and NMR-validated identity and purity.

Biological Rationale

Lisinopril dihydrate is a synthetic, long-acting ACE inhibitor designed to block the conversion of angiotensin I to angiotensin II, a central step in the renin-angiotensin system (RAS) pathway. Angiotensin II is a potent vasoconstrictor and stimulator of aldosterone secretion, driving hypertension and fluid retention (Tieku & Hooper 1992). By inhibiting ACE, Lisinopril dihydrate reduces downstream effects such as vasoconstriction, sodium retention, and sympathetic activation. The compound’s high selectivity arises from its structural mimicry of natural ACE substrates, ensuring minimal off-target effects on other mammalian cell surface peptidases. Its utility in research lies in its ability to model, dissect, and modulate the RAS pathway in preclinical and translational studies of hypertension, heart failure, and renal disease (APExBIO).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate acts as a potent and competitive inhibitor of angiotensin converting enzyme (EC 3.4.15.1). It binds to the active site of ACE, preventing cleavage of the decapeptide angiotensin I to the octapeptide angiotensin II. The IC50 for ACE inhibition by Lisinopril dihydrate is 4.7 nM at pH 8.3 and 37°C (APExBIO). This blockade results in decreased plasma angiotensin II and aldosterone levels, increased plasma renin activity, and reduced blood pressure via vasodilation and decreased fluid retention. The molecular structure incorporates a lysine residue, differentiating it from other ACE inhibitors and conferring high water solubility and prolonged duration of action. Lisinopril dihydrate demonstrates negligible inhibition of aminopeptidases N (AP-N), A (AP-A), and W (AP-W) at micromolar concentrations, supporting its selectivity for ACE (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE with an IC50 of 4.7 nM (pH 8.3, 37°C), enabling precise modulation of the renin-angiotensin system (APExBIO).
• It does not significantly inhibit aminopeptidase N (AP-N), A (AP-A), or W (AP-W) at concentrations up to 10 μM, as confirmed by direct comparative studies (Tieku & Hooper 1992).
• Lisinopril dihydrate is supplied at ≥98% purity, with identity confirmed by mass spectrometry and NMR (APExBIO).
• Solubility in water is ≥2.46 mg/mL with gentle warming and ultrasonic treatment; it is insoluble in ethanol (APExBIO).
• Storage at room temperature in a desiccated state maintains stability for ≥12 months; solutions should not be stored long-term (APExBIO).
• Clinical and preclinical models confirm effective blood pressure reduction and renin-angiotensin system modulation with lisinopril administration (Tieku & Hooper 1992).

Applications, Limits & Misconceptions

Lisinopril dihydrate is extensively used in research on hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. Its high specificity for ACE and favorable pharmacokinetics make it suitable for dissecting the RAS pathway in animal and cell models. APExBIO’s rigorously characterized product ensures reproducibility and reliability in experimental workflows. For advanced protocol guidance and troubleshooting, see our dedicated guide (Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Research), which expands on protocol optimization and troubleshooting not covered here.

Common Pitfalls or Misconceptions

• Misconception: Lisinopril dihydrate inhibits all mammalian cell surface peptidases.
  Correction: It is highly selective for ACE and does not significantly inhibit aminopeptidase N, A, or W at relevant concentrations (Tieku & Hooper 1992).
• Pitfall: Using ethanol as a solvent.
  Correction: Lisinopril dihydrate is insoluble in ethanol; use water with gentle warming for dissolution (APExBIO).
• Misconception: Compound solutions are stable indefinitely.
  Correction: Long-term storage of solutions is not recommended; store solid material desiccated at room temperature (APExBIO).
• Pitfall: Expecting efficacy in non-ACE targets such as AP-N, AP-A, or AP-W.
  Correction: Lisinopril dihydrate shows negligible activity against these enzymes under standard conditions (Tieku & Hooper 1992).
• Misconception: All ACE inhibitors have identical selectivity profiles.
  Correction: Structural analogues may differ in off-target effects; Lisinopril dihydrate’s selectivity profile is verified by direct comparative analysis (Tieku & Hooper 1992).

Workflow Integration & Parameters

Lisinopril dihydrate integrates seamlessly into experimental workflows targeting the renin-angiotensin system. Dissolve at ≥2.46 mg/mL in water, applying gentle warming and ultrasonic treatment as needed. For consistent results, use freshly prepared solutions and maintain the compound at room temperature in a desiccated state. Shipping is on blue ice for small molecule stability. For advanced mechanistic guidance and translational strategies, see Lisinopril Dihydrate in Translational Research, which provides a molecular rationale and strategic comparison of Lisinopril dihydrate applications, complementing the present protocol-focused review. For insights into mechanism and positioning among ACE inhibitors, refer to Translating Mechanistic Precision into Impactful Research, which elaborates on the competitive landscape and visionary use-cases not detailed here.

Conclusion & Outlook

Lisinopril dihydrate is a rigorously validated, long-acting ACE inhibitor that enables precise interrogation of the renin-angiotensin system in hypertension, heart failure, and nephropathy models. Its high selectivity, documented purity, and robust solubility parameters make it a preferred tool for cardiovascular and renal research. Ongoing integration into mechanistic and translational workflows underscores its enduring value for reproducibility and innovation. For detailed specifications and ordering information, visit the APExBIO Lisinopril dihydrate product page.